Rapport Therapeutics, Inc.
Company Stats
- Market Cap
- $1.6B
- as of Sep 30, 2026
- Shares Outstanding
- 48.0M
- Free Float
- 60.2%
Income Statement
- Operating Income
- -$125.1M
- Net Income
- -$111.5M
- EBITDA
- -$124.1M
Cash Flow
- Free Cash Flow
- -$88.1M
- FCF Yield
- -5.5%
- Owner FCF Yield
- -6.6%
Balance Sheet
- Cash & Equivalents
- $52.6M
Returns & Capital
- Share Repurchases
- $1,000
- SBC, 3Y Avg
- $10.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$88.1M | — |
| FY2024 | — | -$67.2M | — |
| FY2023 | — | -$28.8M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Rapport buying stands out relative to size; Beacon brings breadth
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back